Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.30 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406499 | 0.92 | MAPT (0.38) | MAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5445681 | 0.88 | MAPT (0.35) | MAPTSMN1; SMN2KDM4EALDH1A1ADORA2A | |
| SCHEMBL14357594 | 0.88 | TLR7 (0.31) | MAPTLMNA | |
| SCHEMBL5396481 | 0.88 | LMNA (0.33) | MAPTLMNAADORA2AADORA1HTR1A | |
| SCHEMBL5410623 | 0.88 | MAPT (0.38) | MAPTSMN1; SMN2KDM4EALDH1A1LMNA | |
| Bromide SCHEMBL5402709 | 0.86 | MAPT (0.38) | MAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL14357575 | 0.86 | MAPT (0.38) | MAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5399863 | 0.85 | LMNA (0.32) | KDM4EALDH1A1LMNA | |
| SCHEMBL5441226 | 0.83 | LMNA (0.34) | LMNAADORA2AADORA1HTR1AADRA2A | |
| SCHEMBL14357564 | 0.82 | CDK1 (0.36) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300469-B2 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | L'OREAL, SA (FR) | 2007-11-27 | — | — | US | disclosed |
| US-7300469-B2 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | L'OREAL, SA (FR) | 2007-11-27 | — | — | US | disclosed |
| US-7300469-B2 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | L'OREAL, SA (FR) | 2007-11-27 | — | — | US | disclosed |
| US-20040143909-A1 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | L'OREAL S.A. (FR) | 2004-07-29 | — | — | US | disclosed |
| EP-1362036-A1 | DIAMINOPYRAZOLE COMPOUNDS AND THE USE THEREOF IN THE OXIDATION DYEING OF KERATINOUS FIBRES | L'OREAL (FR) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002070489-A1 | DIAMINOPYRAZOLE COMPOUNDS AND THE USE THEREOF IN THE OXIDATION DYEING OF KERATINOUS FIBRES | L'OREAL (FR) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143909-A1 | Diaminopyrazole compounds and the use thereof in the oxidation dyeing of keratinous fibres | KRT18, TUBB3, AOC1 | MAPT 1794/4885SMN1; SMN2 4692/4885KDM4E 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.